Gyre Therapeutics (GYRE) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Shattuck Labs (STTK) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 119.7% versus a loss of 44.2%. Over five years, STTK leads with a -52.0% price change compared with -77.5% for GYRE. Gyre Therapeutics is the larger company by market cap ($460.8 million vs $454.2 million), about 1.0 times the size.
Gyre Therapeutics converts more of its revenue into profit, with a net margin of 8.5% versus -4880.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | STTK |
|---|---|---|
| Share price | $4.21 | $4.46 |
| Market cap | $460.79M | $454.22M |
| 1-day change | -6.86% | -1.98% |
| YTD return | -40.37% | +22.19% |
| 1-year return | -44.24% | +119.70% |
| 5-year return | -77.55% | -51.99% |
| Forward P/E | 70.17 | — |
| EPS (TTM) | $-0.31 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $116.59M | $1.00M |
| Revenue growth (YoY) | +10.24% | -82.52% |
| Net income (latest FY) | $9.88M | $-48.81M |
| Gross margin | 95.35% | — |
| Operating margin | 9.85% | -5150.80% |
| Net margin | 8.47% | -4880.90% |
| 52-week high | $9.14 | $8.33 |
| 52-week low | $3.97 | $1.93 |
| Distance from 52-week high | -53.94% | -46.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +343.47% | +245.29% |
| Average volume | 181.04K | 1.20M |
| Shares outstanding | 109.45M | 101.84M |
| Employees | 625 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed GYRE by 163.9 percentage points over the past year.
- Gyre Therapeutics is more profitable, keeping 8.5 cents of every revenue dollar as net income versus -4880.9 cents for Shattuck Labs.
- Gyre Therapeutics grew revenue faster in its latest fiscal year (+10.24% vs -82.52%).
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
GYRE vs STTK FAQ
Which is bigger, Gyre Therapeutics or Shattuck Labs?
Gyre Therapeutics (GYRE) is larger, with a market capitalization of $460.79M compared with $454.22M for Shattuck Labs (STTK).
Which stock has performed better over the past year, GYRE or STTK?
STTK returned +119.70% over the past 12 months, compared with -44.24% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.